{ "disease": "gastric-cancer", "label": "Gastric cancer", "url": "https://usebiotransfer.org/disease/gastric-cancer/", "built": "2026-09-12", "facts_hash": { "answers": "597d8e761dcc", "targets": "065fc1111139" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-12", "trials": "2026-09-12" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "ERBB2", "ensembl": "ENSG00000141736", "n_drug_entries": 48, "n_distinct_drugs": 45, "drugs": { "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "ANVATABART OPADOTIN": "PHASE_2_3", "AV-412": "PHASE_1", "BMS-690514": "PHASE_2", "CANERTINIB": "PHASE_2", "CP-724714": "PHASE_2", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DISITAMAB VEDOTIN": "PHASE_3", "ERTUMAXOMAB": "PHASE_2", "GANCOTAMAB": "PHASE_2_3", "HEMAY-022": "PHASE_3", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "KN-026": "PHASE_3", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "MARGETUXIMAB": "APPROVAL", "MASOPROCOL": "APPROVAL", "MM-111": "PHASE_2", "MUBRITINIB": "PHASE_1", "NERATINIB": "APPROVAL", "PERTUZUMAB": "APPROVAL", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "TRASTUZUMAB": "APPROVAL", "TRASTUZUMAB BOTIDOTIN": "PHASE_3", "TRASTUZUMAB DERUXTECAN": "APPROVAL", "TRASTUZUMAB DUOCARMAZINE": "APPROVAL", "TRASTUZUMAB EMTANSINE": "APPROVAL", "TUCATINIB": "APPROVAL", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZANIDATAMAB": "APPROVAL", "ZENOCUTUZUMAB": "APPROVAL" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "DACOMITINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "MARGETUXIMAB", "MASOPROCOL", "NERATINIB", "PERTUZUMAB", "TRASTUZUMAB", "TRASTUZUMAB DERUXTECAN", "TRASTUZUMAB DUOCARMAZINE", "TRASTUZUMAB EMTANSINE", "TUCATINIB", "VANDETANIB", "ZANIDATAMAB", "ZENOCUTUZUMAB" ], "n_approved": 17, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "MARGETUXIMAB": [ "HER2 positive breast carcinoma", "breast cancer" ], "MASOPROCOL": [ "prostate cancer" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "PERTUZUMAB": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB": [ "breast cancer", "breast carcinoma", "gastric cancer", "gastric neoplasm", "breast neoplasm" ], "TRASTUZUMAB DERUXTECAN": [ "breast cancer", "HER2 positive breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB DUOCARMAZINE": [], "TRASTUZUMAB EMTANSINE": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TUCATINIB": [ "HER2 positive breast carcinoma", "metastasis", "breast neoplasm", "breast cancer", "colorectal carcinoma", "breast carcinoma" ], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ], "ZANIDATAMAB": [ "biliary tract neoplasm" ], "ZENOCUTUZUMAB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "CLDN18", "ensembl": "ENSG00000066405", "n_drug_entries": 1, "n_distinct_drugs": 1, "drugs": { "ZOLBETUXIMAB": "APPROVAL" }, "approved": [ "ZOLBETUXIMAB" ], "n_approved": 1, "approved_for": { "ZOLBETUXIMAB": [ "gastric cancer", "neoplasm of esophagus", "gastric neoplasm", "gastric adenocarcinoma", "gastroesophageal junction adenocarcinoma" ] }, "tractability": [ { "modality": "AB", "bucket": "Advanced Clinical" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "GO CC med conf" } ] }, { "symbol": "FGFR2", "ensembl": "ENSG00000066468", "n_drug_entries": 27, "n_distinct_drugs": 26, "drugs": { "APRUTUMAB IXADOTIN": "PHASE_1", "BEMARITUZUMAB": "PHASE_3", "BRIVANIB": "PHASE_3", "BRIVANIB ALANINATE": "PHASE_3", "DERAZANTINIB": "PHASE_3", "E-7090": "APPROVAL", "ENMD-981693": "PHASE_2", "ERDAFITINIB": "APPROVAL", "FEXAGRATINIB": "PHASE_2", "FGFR INHIBITOR DEBIO 1347": "PHASE_2", "FUTIBATINIB": "APPROVAL", "HMPL-453": "PHASE_2", "INFIGRATINIB": "APPROVAL", "LUCITANIB": "PHASE_3", "LY-2874455": "PHASE_2", "NINTEDANIB": "APPROVAL", "NINTEDANIB ESYLATE": "APPROVAL", "ORANTINIB": "PHASE_3", "PALIFERMIN": "APPROVAL", "PEMIGATINIB": "APPROVAL", "REGORAFENIB": "APPROVAL", "RG-1530": "PHASE_1", "ROGARATINIB": "PHASE_2_3", "TG100-801": "PHASE_2", "TRAFERMIN": "APPROVAL", "XL-999": "PHASE_2" }, "approved": [ "E-7090", "ERDAFITINIB", "FUTIBATINIB", "INFIGRATINIB", "NINTEDANIB", "NINTEDANIB ESYLATE", "PALIFERMIN", "PEMIGATINIB", "REGORAFENIB", "TRAFERMIN" ], "n_approved": 10, "approved_for": { "E-7090": [ "biliary tract cancer" ], "ERDAFITINIB": [ "urothelial carcinoma", "urinary bladder carcinoma" ], "FUTIBATINIB": [ "biliary tract cancer", "intrahepatic cholangiocarcinoma", "cholangiocarcinoma" ], "INFIGRATINIB": [ "cholangiocarcinoma" ], "NINTEDANIB": [ "idiopathic pulmonary fibrosis", "colorectal cancer", "interstitial lung disease", "systemic sclerosis", "pulmonary fibrosis" ], "NINTEDANIB ESYLATE": [ "idiopathic pulmonary fibrosis", "systemic sclerosis", "non-small cell lung carcinoma", "Interstitial pneumonitis" ], "PALIFERMIN": [ "oral mucositis", "mucositis" ], "PEMIGATINIB": [ "biliary tract cancer", "cholangiocarcinoma" ], "REGORAFENIB": [ "colorectal cancer", "metastatic colorectal cancer", "colorectal neoplasm" ], "TRAFERMIN": [ "periodontitis", "Skin ulcer" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Advanced Clinical" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "MET", "ensembl": "ENSG00000105976", "n_drug_entries": 38, "n_distinct_drugs": 36, "drugs": { "ALTIRATINIB": "PHASE_1", "AMG-208": "PHASE_2", "AMG-337": "PHASE_2", "AMIVANTAMAB": "APPROVAL", "AMUVATINIB": "PHASE_2", "ARRY-300": "PHASE_1", "BAFISONTAMAB": "PHASE_2", "BEPERMINOGENE PERPLASMID": "PHASE_3", "BMS-777607": "PHASE_1_2", "BMS-817378": "PHASE_1", "BPI-9016": "PHASE_1", "CABOZANTINIB": "APPROVAL", "CABOZANTINIB S-MALATE": "APPROVAL", "CAPMATINIB": "APPROVAL", "CRIZOTINIB": "APPROVAL", "EMD-1204831": "PHASE_1", "EMIBETUZUMAB": "PHASE_2", "FORETINIB": "PHASE_2", "GLESATINIB": "PHASE_2", "GOLVATINIB": "PHASE_1_2", "JNJ-38877605": "PHASE_1", "MERESTINIB": "PHASE_2", "MK-2461": "PHASE_1_2", "MK-8033": "PHASE_1", "NINGETINIB": "PHASE_2", "ONARTUZUMAB": "PHASE_3", "PF-04217903": "PHASE_1", "SAR-125844": "PHASE_2", "SAVOLITINIB": "PHASE_3", "SGX-523": "PHASE_1", "TAS-115": "PHASE_1", "TELISOTUZUMAB": "PHASE_1", "TELISOTUZUMAB VEDOTIN": "PHASE_3", "TEPOTINIB": "APPROVAL", "TEREVALEFIM": "PHASE_3", "TIVANTINIB": "PHASE_3" }, "approved": [ "AMIVANTAMAB", "CABOZANTINIB", "CABOZANTINIB S-MALATE", "CAPMATINIB", "CRIZOTINIB", "TEPOTINIB" ], "n_approved": 6, "approved_for": { "AMIVANTAMAB": [ "non-small cell lung carcinoma" ], "CABOZANTINIB": [ "thyroid cancer", "thyroid tumor", "hepatocellular carcinoma", "renal cell carcinoma", "medullary thyroid gland carcinoma" ], "CABOZANTINIB S-MALATE": [ "thyroid gland carcinoma", "renal cell carcinoma" ], "CAPMATINIB": [ "non-small cell lung carcinoma" ], "CRIZOTINIB": [ "non-small cell lung carcinoma" ], "TEPOTINIB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "CDH1", "ensembl": "ENSG00000039068", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "PIK3CA", "ensembl": "ENSG00000121879", "n_drug_entries": 32, "n_distinct_drugs": 31, "drugs": { "ALPELISIB": "APPROVAL", "APITOLISIB": "PHASE_2", "AZD-6482": "UNKNOWN", "BAY-1082439": "PHASE_1", "BGT-226": "PHASE_1_2", "BUPARLISIB": "PHASE_3", "COPANLISIB": "APPROVAL", "DACTOLISIB": "PHASE_3", "DS-7423": "PHASE_1", "FIMEPINOSTAT": "PHASE_2", "GEDATOLISIB": "PHASE_3", "GSK-1059615": "PHASE_1", "INAVOLISIB": "APPROVAL", "IZORLISIB": "PHASE_1_2", "OMIPALISIB": "PHASE_1", "PANULISIB": "PHASE_1", "PAXALISIB": "PHASE_2_3", "PF-04691502": "PHASE_2", "PICTILISIB": "PHASE_2", "PILARALISIB": "PHASE_2", "PKI-179": "PHASE_1", "RECILISIB": "PHASE_1", "SAMOTOLISIB": "PHASE_2", "SERABELISIB": "PHASE_2", "SF-1126": "PHASE_2", "SONOLISIB": "PHASE_2", "TASELISIB": "PHASE_3", "VOXTALISIB": "PHASE_2", "VS-5584": "PHASE_1", "WX-037": "PHASE_1", "ZSTK-474": "PHASE_1" }, "approved": [ "ALPELISIB", "COPANLISIB", "INAVOLISIB" ], "n_approved": 3, "approved_for": { "ALPELISIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "COPANLISIB": [ "follicular lymphoma", "non-Hodgkin lymphoma", "neoplasm of mature B-cells" ], "INAVOLISIB": [ "breast neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "KRAS", "ensembl": "ENSG00000133703", "n_drug_entries": 3, "n_distinct_drugs": 3, "drugs": { "ADAGRASIB": "APPROVAL", "SALIRASIB": "PHASE_2", "SOTORASIB": "APPROVAL" }, "approved": [ "ADAGRASIB", "SOTORASIB" ], "n_approved": 2, "approved_for": { "ADAGRASIB": [ "non-small cell lung carcinoma" ], "SOTORASIB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "ARID1A", "ensembl": "ENSG00000117713", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "RHOA", "ensembl": "ENSG00000067560", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "CD274", "ensembl": "ENSG00000120217", "n_drug_entries": 13, "n_distinct_drugs": 13, "drugs": { "ADEBRELIMAB": "PHASE_3", "ATEZOLIZUMAB": "APPROVAL", "AVELUMAB": "APPROVAL", "BINTRAFUSP ALFA": "PHASE_3", "COSIBELIMAB": "APPROVAL", "DANBURSTOTUG": "PHASE_2", "DURVALUMAB": "APPROVAL", "ENVAFOLIMAB": "PHASE_3", "ERFONRILIMAB": "PHASE_3", "INCB-086550": "PHASE_2", "PACMILIMAB": "PHASE_2", "SOCAZOLIMAB": "PHASE_3", "SUGEMALIMAB": "APPROVAL" }, "approved": [ "ATEZOLIZUMAB", "AVELUMAB", "COSIBELIMAB", "DURVALUMAB", "SUGEMALIMAB" ], "n_approved": 5, "approved_for": { "ATEZOLIZUMAB": [ "urothelial carcinoma", "non-small cell lung carcinoma", "breast cancer", "small cell lung carcinoma", "breast neoplasm", "transitional cell carcinoma" ], "AVELUMAB": [ "Merkel cell skin cancer", "urothelial carcinoma", "neuroendocrine neoplasm" ], "COSIBELIMAB": [ "head and neck squamous cell carcinoma" ], "DURVALUMAB": [ "non-small cell lung carcinoma", "small cell lung carcinoma", "urothelial carcinoma", "hepatocellular carcinoma" ], "SUGEMALIMAB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "KDR", "ensembl": "ENSG00000128052", "n_drug_entries": 75, "n_distinct_drugs": 70, "drugs": { "4SC-203": "PHASE_1", "AEE-788": "PHASE_1_2", "ALACIZUMAB PEGOL": "PHASE_2", "ALTIRATINIB": "PHASE_1", "AXITINIB": "APPROVAL", "BFH-772": "PHASE_2", "BMS-690514": "PHASE_2", "BMS-817378": "PHASE_1", "BRIVANIB": "PHASE_3", "BRIVANIB ALANINATE": "PHASE_3", "CABOZANTINIB": "APPROVAL", "CABOZANTINIB S-MALATE": "APPROVAL", "CATEQUENTINIB": "PHASE_3", "CEDIRANIB": "APPROVAL", "CEP-11981": "PHASE_2", "CEP-5214": "UNKNOWN", "CM-082": "PHASE_2", "CYC-116": "PHASE_1", "DOVITINIB": "PHASE_3", "ENMD-2076": "PHASE_2", "ENMD-981693": "PHASE_2", "FAMITINIB": "PHASE_3", "FORETINIB": "PHASE_2", "FRUQUINTINIB": "APPROVAL", "GLESATINIB": "PHASE_2", "GOLVATINIB": "PHASE_1_2", "HENATINIB": "PHASE_1", "IBCASERTIB": "PHASE_3", "ILORASERTIB": "PHASE_2", "IMC-1C11": "PHASE_1", "JI-101": "PHASE_2", "KRN-633": "PHASE_1", "LENVATINIB": "APPROVAL", "LINIFANIB": "PHASE_3", "LUCITANIB": "PHASE_3", "MIDOSTAURIN": "APPROVAL", "MOTESANIB": "PHASE_3", "NINGETINIB": "PHASE_2", "NINTEDANIB": "APPROVAL", "NINTEDANIB ESYLATE": "APPROVAL", "OLINVACIMAB": "PHASE_2", "ORANTINIB": "PHASE_3", "OSI-632": "PHASE_2", "OSI-930": "PHASE_1", "PAZOPANIB": "APPROVAL", "PEGDINETANIB": "PHASE_2", "PF-00337210": "PHASE_1", "RAF-265": "PHASE_2", "RAMUCIRUMAB": "APPROVAL", "REGORAFENIB": "APPROVAL", "RG-1530": "PHASE_1", "RIVOCERANIB": "APPROVAL", "SEMAXANIB": "PHASE_3", "SORAFENIB": "APPROVAL", "SU-014813": "PHASE_2", "SUNITINIB": "APPROVAL", "SUNITINIB MALATE": "APPROVAL", "SURUFATINIB": "APPROVAL", "TAK-593": "PHASE_1", "TAS-115": "PHASE_1", "TELATINIB": "PHASE_2", "TELBERMIN": "PHASE_2", "TG100-801": "PHASE_2", "TIVOZANIB": "APPROVAL", "VANDETANIB": "APPROVAL", "VATALANIB": "PHASE_3", "X-82": "PHASE_2", "XL-820": "PHASE_2", "XL-999": "PHASE_2", "ZD-4190": "UNKNOWN" }, "approved": [ "AXITINIB", "CABOZANTINIB", "CABOZANTINIB S-MALATE", "CEDIRANIB", "FRUQUINTINIB", "LENVATINIB", "MIDOSTAURIN", "NINTEDANIB", "NINTEDANIB ESYLATE", "PAZOPANIB", "RAMUCIRUMAB", "REGORAFENIB", "RIVOCERANIB", "SORAFENIB", "SUNITINIB", "SUNITINIB MALATE", "SURUFATINIB", "TIVOZANIB", "VANDETANIB" ], "n_approved": 19, "approved_for": { "AXITINIB": [ "renal cell carcinoma" ], "CABOZANTINIB": [ "thyroid cancer", "thyroid tumor", "hepatocellular carcinoma", "renal cell carcinoma", "medullary thyroid gland carcinoma" ], "CABOZANTINIB S-MALATE": [ "thyroid gland carcinoma", "renal cell carcinoma" ], "CEDIRANIB": [], "FRUQUINTINIB": [ "colorectal cancer", "colorectal neoplasm" ], "LENVATINIB": [ "thyroid cancer", "thyroid tumor", "renal cell carcinoma", "differentiated thyroid carcinoma", "thyroid gland carcinoma" ], "MIDOSTAURIN": [ "mast cell leukemia", "mastocytosis", "acute myeloid leukemia by FAB classification", "systemic mastocytosis", "acute myeloid leukemia" ], "NINTEDANIB": [ "idiopathic pulmonary fibrosis", "colorectal cancer", "interstitial lung disease", "systemic sclerosis", "pulmonary fibrosis" ], "NINTEDANIB ESYLATE": [ "idiopathic pulmonary fibrosis", "systemic sclerosis", "non-small cell lung carcinoma", "Interstitial pneumonitis" ], "PAZOPANIB": [ "soft tissue sarcoma", "renal cell carcinoma", "sarcoma" ], "RAMUCIRUMAB": [ "gastric cancer", "non-small cell lung carcinoma", "gastric adenocarcinoma", "gastric neoplasm", "gastroesophageal junction adenocarcinoma" ], "REGORAFENIB": [ "colorectal cancer", "metastatic colorectal cancer", "colorectal neoplasm" ], "RIVOCERANIB": [ "breast cancer" ], "SORAFENIB": [ "renal cell carcinoma", "thyroid gland carcinoma", "hepatocellular carcinoma" ], "SUNITINIB": [ "gastrointestinal stromal tumor", "renal cell carcinoma", "neuroendocrine neoplasm" ], "SUNITINIB MALATE": [ "renal cell carcinoma", "gastrointestinal stromal tumor", "neuroendocrine neoplasm" ], "SURUFATINIB": [], "TIVOZANIB": [ "renal cell carcinoma" ], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] } ], "trials": { "by_antigen": { "HER2": { "n": 267, "n_observational": 28, "n_active": 109, "n_withdrawn": 10, "trials": [ { "nct": "NCT03740256", "title": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05150691", "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05274048", "title": "Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients", "status": "RECRUITING", "last_update": "2025-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05427383", "title": "KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy", "status": "RECRUITING", "last_update": "2023-12-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05523947", "title": "Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05640830", "title": "Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy", "status": "RECRUITING", "last_update": "2024-11-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05671822", "title": "Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer", "status": "RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05677490", "title": "mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05894824", "title": "T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma", "status": "RECRUITING", "last_update": "2025-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05918094", "title": "Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "RECRUITING", "last_update": "2024-01-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05965479", "title": "Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06023758", "title": "Phase 2 Trial of KN026+KN046\u00b1XELOX in HER2-positive Locally Advanced GC", "status": "RECRUITING", "last_update": "2024-05-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06085755", "title": "Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06121700", "title": "Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer", "status": "RECRUITING", "last_update": "2023-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123494", "title": "SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen", "status": "RECRUITING", "last_update": "2024-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253650", "title": "Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease", "status": "RECRUITING", "last_update": "2024-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06330064", "title": "A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364410", "title": "Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06468280", "title": "Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06487429", "title": "Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer", "status": "RECRUITING", "last_update": "2024-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06504732", "title": "To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532006", "title": "A Phase \u2162 Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06572319", "title": "Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens", "status": "RECRUITING", "last_update": "2024-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06630130", "title": "Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06632262", "title": "A Phase 2 Clinical Study of ABSK061 and ABSK043", "status": "RECRUITING", "last_update": "2024-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06650332", "title": "Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients", "status": "RECRUITING", "last_update": "2024-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06715839", "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06730373", "title": "First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)", "status": "RECRUITING", "last_update": "2024-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06731478", "title": "Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06750185", "title": "Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760819", "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764875", "title": "A Phase \u2162 Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773312", "title": "BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.", "status": "RECRUITING", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06774222", "title": "A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG", "status": "RECRUITING", "last_update": "2025-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07056010", "title": "Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07069712", "title": "A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07176312", "title": "Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07192432", "title": "Gene Therapy for HER-Positive Cancer (SENTRY-HER2)", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07194005", "title": "Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer", "status": "RECRUITING", "last_update": "2025-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07315750", "title": "A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07334431", "title": "Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07551362", "title": "Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07607119", "title": "PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07655024", "title": "TAIC FOLFOX for Locally Advanced G/GEJA", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07660055", "title": "Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07673887", "title": "A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07788196", "title": "A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005956", "title": "Biological Therapy in Treating Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2014-07-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017537", "title": "Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer", "status": "WITHDRAWN", "last_update": "2013-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00028535", "title": "Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00291473", "title": "Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers", "status": "COMPLETED", "last_update": "2009-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00450203", "title": "Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer", "status": "UNKNOWN", "last_update": "2016-12-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00515411", "title": "Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2019-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00680901", "title": "LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01041404", "title": "ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2014-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01123473", "title": "Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer", "status": "TERMINATED", "last_update": "2016-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130337", "title": "A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer", "status": "COMPLETED", "last_update": "2015-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01145404", "title": "Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer", "status": "TERMINATED", "last_update": "2014-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01148849", "title": "Safety Study of MGAH22 in HER2-positive Carcinomas", "status": "COMPLETED", "last_update": "2025-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01191697", "title": "CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2025-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01228045", "title": "A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01260194", "title": "A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer", "status": "TERMINATED", "last_update": "2016-11-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01295086", "title": "Taxotere\u00ae, Eloxatin\u00ae and Xeloda\u00ae (TEX) in Combination With Herceptin\u00ae as Treatment for HER2 Positive Non-resectable Cancer", "status": "COMPLETED", "last_update": "2020-11-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01359397", "title": "Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01364493", "title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2017-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01384253", "title": "Safety Study of \u00b2\u00b9\u00b2Pb-TCMC-Trastuzumab Radio Immunotherapy", "status": "COMPLETED", "last_update": "2016-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01396707", "title": "Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX", "status": "COMPLETED", "last_update": "2020-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01402401", "title": "Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients", "status": "TERMINATED", "last_update": "2020-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01450696", "title": "A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer", "status": "TERMINATED", "last_update": "2016-11-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01461057", "title": "A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01472029", "title": "Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach", "status": "COMPLETED", "last_update": "2017-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01503983", "title": "Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive", "status": "COMPLETED", "last_update": "2015-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01576666", "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01579578", "title": "Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer", "status": "TERMINATED", "last_update": "2014-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01590719", "title": "A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2016-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01598077", "title": "A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602406", "title": "Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01613950", "title": "PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01614522", "title": "A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2", "status": "COMPLETED", "last_update": "2015-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01624025", "title": "A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin", "status": "COMPLETED", "last_update": "2016-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01641939", "title": "A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer", "status": "TERMINATED", "last_update": "2017-05-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01649271", "title": "Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.", "status": "COMPLETED", "last_update": "2025-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01702558", "title": "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)", "status": "TERMINATED", "last_update": "2021-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01736410", "title": "A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2013-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01746771", "title": "A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2016-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01748773", "title": "A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2019-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01774786", "title": "A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer", "status": "COMPLETED", "last_update": "2020-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01774851", "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach", "status": "TERMINATED", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01847794", "title": "HER2 Positive CTC in Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2013-05-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928290", "title": "Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01939275", "title": "64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer", "status": "COMPLETED", "last_update": "2025-02-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02004769", "title": "Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2016-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02005484", "title": "A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression", "status": "TERMINATED", "last_update": "2014-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02015169", "title": "Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis", "status": "COMPLETED", "last_update": "2018-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02030561", "title": "NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02158988", "title": "Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis", "status": "COMPLETED", "last_update": "2021-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205047", "title": "Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205463", "title": "KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer", "status": "WITHDRAWN", "last_update": "2014-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02240212", "title": "Study of Afuresertib Combined With Paclitaxel in Gastric Cancer", "status": "COMPLETED", "last_update": "2017-04-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02250209", "title": "T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy", "status": "UNKNOWN", "last_update": "2014-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274012", "title": "Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment", "status": "WITHDRAWN", "last_update": "2017-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02276300", "title": "HER2-Peptide Vaccination of Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2019-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02344810", "title": "C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer", "status": "WITHDRAWN", "last_update": "2023-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02358863", "title": "Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach", "status": "TERMINATED", "last_update": "2018-09-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02378389", "title": "Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2015-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02380131", "title": "Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis", "status": "UNKNOWN", "last_update": "2015-03-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02393248", "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)", "status": "TERMINATED", "last_update": "2023-01-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02442414", "title": "A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02445209", "title": "Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma", "status": "COMPLETED", "last_update": "2015-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02500199", "title": "Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors", "status": "UNKNOWN", "last_update": "2021-02-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02512237", "title": "A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression", "status": "TERMINATED", "last_update": "2020-06-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02576548", "title": "A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.", "status": "COMPLETED", "last_update": "2019-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02578368", "title": "Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction", "status": "COMPLETED", "last_update": "2024-11-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02581462", "title": "FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer", "status": "COMPLETED", "last_update": "2020-08-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02662348", "title": "T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System", "status": "UNKNOWN", "last_update": "2016-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02678182", "title": "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02713984", "title": "A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer", "status": "WITHDRAWN", "last_update": "2020-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02725424", "title": "Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2022-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02726399", "title": "Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer", "status": "TERMINATED", "last_update": "2020-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02805829", "title": "Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02852096", "title": "Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks", "status": "UNKNOWN", "last_update": "2017-11-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02901301", "title": "Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02951091", "title": "Biomarker-Integrated Umbrella, Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952729", "title": "Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954536", "title": "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer", "status": "COMPLETED", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319459", "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2021-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03329690", "title": "DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]", "status": "COMPLETED", "last_update": "2022-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03330561", "title": "PRS-343 in HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03368196", "title": "DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein", "status": "COMPLETED", "last_update": "2022-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409848", "title": "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03556345", "title": "A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2", "status": "COMPLETED", "last_update": "2022-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03588533", "title": "Herzuma-capecitabine/Cisplatin for Gastric Cancer", "status": "UNKNOWN", "last_update": "2018-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03602079", "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene", "status": "COMPLETED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03615326", "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)", "status": "COMPLETED", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03619681", "title": "Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer", "status": "COMPLETED", "last_update": "2024-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03675737", "title": "Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03680560", "title": "Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers", "status": "TERMINATED", "last_update": "2020-03-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766607", "title": "Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer", "status": "WITHDRAWN", "last_update": "2019-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03783936", "title": "Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03821233", "title": "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers", "status": "COMPLETED", "last_update": "2025-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924466", "title": "Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients", "status": "UNKNOWN", "last_update": "2024-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03950271", "title": "SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04014075", "title": "DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)", "status": "COMPLETED", "last_update": "2025-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04082364", "title": "Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04168931", "title": "Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC", "status": "TERMINATED", "last_update": "2023-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04248452", "title": "Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04249739", "title": "Pembrolizumab + Capecitabine\uff0fOxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive", "status": "UNKNOWN", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04276493", "title": "Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04281576", "title": "Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2024-11-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04309578", "title": "A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04319757", "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors", "status": "COMPLETED", "last_update": "2024-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439110", "title": "Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04467515", "title": "A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer", "status": "TERMINATED", "last_update": "2025-05-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04492488", "title": "A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2025-01-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510064", "title": "Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma\uff1aFDZL-GC001 Trial", "status": "COMPLETED", "last_update": "2025-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "status": "TERMINATED", "last_update": "2023-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04511871", "title": "A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04584008", "title": "Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "status": "WITHDRAWN", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04604132", "title": "Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639219", "title": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "status": "UNKNOWN", "last_update": "2024-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04661150", "title": "A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction", "status": "COMPLETED", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704934", "title": "Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04714190", "title": "A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression", "status": "UNKNOWN", "last_update": "2023-12-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04819971", "title": "Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC", "status": "UNKNOWN", "last_update": "2023-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04859582", "title": "Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension", "status": "WITHDRAWN", "last_update": "2021-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04888663", "title": "Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)", "status": "UNKNOWN", "last_update": "2021-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04908813", "title": "Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04989816", "title": "Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens", "status": "COMPLETED", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05002127", "title": "A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05013554", "title": "Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05034887", "title": "Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05076591", "title": "IMM2902, a HER2/SIRP\u03b1 Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors", "status": "SUSPENDED", "last_update": "2024-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05113459", "title": "Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer\uff08RC48-C018\uff09", "status": "UNKNOWN", "last_update": "2021-11-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05141747", "title": "A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.", "status": "UNKNOWN", "last_update": "2022-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05143970", "title": "A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05162755", "title": "S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers", "status": "COMPLETED", "last_update": "2026-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05188209", "title": "A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.", "status": "TERMINATED", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05190445", "title": "Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05207722", "title": "CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-12-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05218148", "title": "SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma", "status": "UNKNOWN", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05246982", "title": "HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05270889", "title": "Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial", "status": "UNKNOWN", "last_update": "2022-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311176", "title": "A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)", "status": "TERMINATED", "last_update": "2025-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311189", "title": "Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05382364", "title": "Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05400915", "title": "Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients", "status": "COMPLETED", "last_update": "2023-11-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05472532", "title": "Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)", "status": "COMPLETED", "last_update": "2025-11-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05515796", "title": "Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors", "status": "COMPLETED", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05555251", "title": "BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-12-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05608785", "title": "Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes", "status": "UNKNOWN", "last_update": "2022-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05627414", "title": "Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05678205", "title": "A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors", "status": "WITHDRAWN", "last_update": "2025-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05715931", "title": "Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05765357", "title": "Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin\u00ae in Healthy Male Volunteers", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05805956", "title": "IMM2902 in Patients With Advanced Solid Tumors Expressing HER2", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05928897", "title": "Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab", "status": "UNKNOWN", "last_update": "2023-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05955833", "title": "89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study", "status": "COMPLETED", "last_update": "2026-05-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05980481", "title": "A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05997524", "title": "Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.", "status": "COMPLETED", "last_update": "2023-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06036745", "title": "Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06098898", "title": "Safety and Efficacy of NK510 to Treat Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-10-25", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06109467", "title": "Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06136897", "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06157892", "title": "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06256328", "title": "A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-na\u00efve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06271837", "title": "A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06284746", "title": "Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2024-02-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06328738", "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06439550", "title": "Adjuvant Treatment With Serplulimab\uff0cTrastuzumab and SOX in the HER-2 Positive GC/GEJC", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06748508", "title": "Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06881017", "title": "Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06944496", "title": "A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06992024", "title": "Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998771", "title": "JSKN003 Combined Treatment of HER2-positive Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07036185", "title": "A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07040059", "title": "A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "TERMINATED", "last_update": "2026-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07126561", "title": "Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07243938", "title": "Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07257380", "title": "Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332533", "title": "A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07490990", "title": "Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07507526", "title": "A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07508956", "title": "Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07529613", "title": "Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2026-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07602140", "title": "TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07631884", "title": "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07685704", "title": "Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07700979", "title": "Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07801027", "title": "A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 4, "n_observational": 1, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT07551362", "title": "Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02030561", "title": "NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02713984", "title": "A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer", "status": "WITHDRAWN", "last_update": "2020-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "HER2", "ERBB2", "trastuzumab", "trastuzumab deruxtecan", "zanidatamab" ] }, "CLDN18.2": { "n": 71, "n_observational": 8, "n_active": 47, "n_withdrawn": 2, "trials": [ { "nct": "NCT05365581", "title": "A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05482893", "title": "Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05620732", "title": "Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T", "status": "RECRUITING", "last_update": "2022-11-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05702229", "title": "Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05934331", "title": "A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study", "status": "RECRUITING", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06005493", "title": "Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06177041", "title": "M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.", "status": "RECRUITING", "last_update": "2024-02-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06219941", "title": "AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06468280", "title": "Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06519591", "title": "Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06602037", "title": "ImmunoPET Imaging of Pancreatic Cancer", "status": "RECRUITING", "last_update": "2025-12-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06732856", "title": "A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2025-07-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06901531", "title": "A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06921837", "title": "A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer", "status": "RECRUITING", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06962137", "title": "Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer", "status": "RECRUITING", "last_update": "2025-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07025889", "title": "IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07103668", "title": "A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients", "status": "RECRUITING", "last_update": "2025-10-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07385703", "title": "Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07432295", "title": "Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07488676", "title": "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07518147", "title": "A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07551362", "title": "Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07556640", "title": "LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07595237", "title": "A IIT Study of 177Lu-DOTA-SNA040", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07673887", "title": "A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01197885", "title": "Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01630083", "title": "Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer", "status": "COMPLETED", "last_update": "2025-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01671774", "title": "Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer", "status": "COMPLETED", "last_update": "2024-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03504397", "title": "A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03528629", "title": "A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "status": "COMPLETED", "last_update": "2024-12-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03653507", "title": "A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03890198", "title": "A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma", "status": "TERMINATED", "last_update": "2020-07-02", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04086758", "title": "A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "status": "COMPLETED", "last_update": "2024-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04400383", "title": "Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-05-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04404595", "title": "Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04581473", "title": "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04683939", "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors", "status": "TERMINATED", "last_update": "2024-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04805307", "title": "Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901", "status": "COMPLETED", "last_update": "2025-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05009966", "title": "Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor", "status": "UNKNOWN", "last_update": "2021-10-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05043987", "title": "Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers", "status": "WITHDRAWN", "last_update": "2023-09-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05156866", "title": "First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05159440", "title": "First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05181865", "title": "Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2022-02-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05277987", "title": "An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects", "status": "UNKNOWN", "last_update": "2022-03-14", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05393986", "title": "Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors", "status": "UNKNOWN", "last_update": "2023-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05472857", "title": "Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression", "status": "UNKNOWN", "last_update": "2024-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05525286", "title": "Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma", "status": "TERMINATED", "last_update": "2025-11-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05539430", "title": "Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05583201", "title": "NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors", "status": "UNKNOWN", "last_update": "2023-02-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05608785", "title": "Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes", "status": "UNKNOWN", "last_update": "2022-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05632939", "title": "ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05937919", "title": "68Ga-PMD22 PET/CT Examination Targeting CLDN18.2", "status": "UNKNOWN", "last_update": "2023-07-10", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05952375", "title": "Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial", "status": "UNKNOWN", "last_update": "2023-07-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05980416", "title": "Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2", "status": "TERMINATED", "last_update": "2025-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06093425", "title": "Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06134960", "title": "NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor", "status": "NOT_YET_RECRUITING", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06203613", "title": "Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer", "status": "UNKNOWN", "last_update": "2024-02-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06222944", "title": "Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA", "status": "UNKNOWN", "last_update": "2024-01-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06346392", "title": "AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06464965", "title": "Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer", "status": "COMPLETED", "last_update": "2026-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06646783", "title": "Phase IIT Trial of SNA014", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06792435", "title": "XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06881017", "title": "Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06921928", "title": "Study for AZD4360 in Participants With Advanced Solid Tumours", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06942767", "title": "Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07143604", "title": "A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07394205", "title": "Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 14, "n_observational": 0, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT05620732", "title": "Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T", "status": "RECRUITING", "last_update": "2022-11-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07551362", "title": "Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04404595", "title": "Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04581473", "title": "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05277987", "title": "An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects", "status": "UNKNOWN", "last_update": "2022-03-14", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05393986", "title": "Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors", "status": "UNKNOWN", "last_update": "2023-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05472857", "title": "Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression", "status": "UNKNOWN", "last_update": "2024-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05539430", "title": "Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05583201", "title": "NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors", "status": "UNKNOWN", "last_update": "2023-02-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05952375", "title": "Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial", "status": "UNKNOWN", "last_update": "2023-07-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06134960", "title": "NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor", "status": "NOT_YET_RECRUITING", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06464965", "title": "Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer", "status": "COMPLETED", "last_update": "2026-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07394205", "title": "Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CLDN18.2", "claudin 18.2", "claudin-18.2", "zolbetuximab", "Vyloy", "osemitamab" ] }, "PD-1": { "n": 415, "n_observational": 30, "n_active": 191, "n_withdrawn": 7, "trials": [ { "nct": "NCT03259867", "title": "Combination of TATE and PD-1 Inhibitor in Liver Cancer", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03526835", "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04114136", "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04198766", "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282044", "title": "Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies", "status": "RECRUITING", "last_update": "2024-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04519151", "title": "Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer", "status": "RECRUITING", "last_update": "2023-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04592211", "title": "Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer", "status": "RECRUITING", "last_update": "2025-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895709", "title": "A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04900818", "title": "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04997837", "title": "Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma", "status": "RECRUITING", "last_update": "2021-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05033392", "title": "PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer", "status": "RECRUITING", "last_update": "2025-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05177133", "title": "Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)", "status": "RECRUITING", "last_update": "2024-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187338", "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05208762", "title": "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05269381", "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05319639", "title": "Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab", "status": "RECRUITING", "last_update": "2025-02-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05365581", "title": "A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05438459", "title": "GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05482893", "title": "Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05536102", "title": "The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)", "status": "RECRUITING", "last_update": "2023-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05593458", "title": "Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05677490", "title": "mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05687357", "title": "Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma", "status": "RECRUITING", "last_update": "2023-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05699655", "title": "Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV\u3001Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2024-05-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05702229", "title": "Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768932", "title": "BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05918094", "title": "Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "RECRUITING", "last_update": "2024-01-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05934331", "title": "A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study", "status": "RECRUITING", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941507", "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06121700", "title": "Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer", "status": "RECRUITING", "last_update": "2023-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06157996", "title": "Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore", "status": "RECRUITING", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06158919", "title": "A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer", "status": "RECRUITING", "last_update": "2023-12-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06203600", "title": "Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253611", "title": "First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS \u22655 Metastatic Gastric Cancer", "status": "RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06346093", "title": "Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2025-06-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06346197", "title": "Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06371586", "title": "Neo-Sequence 2\uff1aNCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC", "status": "RECRUITING", "last_update": "2024-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06427941", "title": "A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06451211", "title": "Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer", "status": "RECRUITING", "last_update": "2024-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06468280", "title": "Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532006", "title": "A Phase \u2162 Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532799", "title": "TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06560528", "title": "Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression", "status": "RECRUITING", "last_update": "2024-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06580574", "title": "Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06597227", "title": "Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06685887", "title": "A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis", "status": "RECRUITING", "last_update": "2025-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06731478", "title": "Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764875", "title": "A Phase \u2162 Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06789172", "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06793917", "title": "Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "RECRUITING", "last_update": "2025-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06826079", "title": "Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06901531", "title": "A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07007182", "title": "Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer", "status": "RECRUITING", "last_update": "2026-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07023315", "title": "A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07056010", "title": "Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07059299", "title": "A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07115043", "title": "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07149090", "title": "Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites", "status": "RECRUITING", "last_update": "2025-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07176312", "title": "Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07221149", "title": "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07223424", "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07227168", "title": "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07262619", "title": "EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07263386", "title": "A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer", "status": "RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07315750", "title": "A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07334119", "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07385703", "title": "Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392892", "title": "Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07432295", "title": "Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07517107", "title": "Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07537361", "title": "Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer", "status": "RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554521", "title": "A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07673887", "title": "A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07699939", "title": "Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07749586", "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013154", "title": "A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab", "status": "COMPLETED", "last_update": "2025-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02178722", "title": "Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers", "status": "COMPLETED", "last_update": "2022-02-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02267343", "title": "Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer", "status": "COMPLETED", "last_update": "2024-05-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02335411", "title": "A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)", "status": "COMPLETED", "last_update": "2022-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02346955", "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)", "status": "TERMINATED", "last_update": "2020-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02370498", "title": "A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)", "status": "COMPLETED", "last_update": "2022-06-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02393248", "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)", "status": "TERMINATED", "last_update": "2023-01-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02443324", "title": "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer", "status": "COMPLETED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02494583", "title": "Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)", "status": "COMPLETED", "last_update": "2023-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02563548", "title": "A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02572687", "title": "A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies", "status": "COMPLETED", "last_update": "2021-01-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02578368", "title": "Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction", "status": "COMPLETED", "last_update": "2024-11-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02599324", "title": "Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors", "status": "COMPLETED", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02635672", "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2024-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689284", "title": "Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02730546", "title": "Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2025-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02746796", "title": "Study of ONO-4538 in Gastric Cancer", "status": "COMPLETED", "last_update": "2024-05-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02757391", "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors", "status": "TERMINATED", "last_update": "2020-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02830594", "title": "Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2024-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02862028", "title": "PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)", "status": "UNKNOWN", "last_update": "2016-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02862535", "title": "Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "TERMINATED", "last_update": "2020-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02872116", "title": "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02901301", "title": "Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02903914", "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02915432", "title": "The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC", "status": "UNKNOWN", "last_update": "2021-12-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02918162", "title": "Perioperative Chemo and Pembrolizumab in Gastric Cancer", "status": "COMPLETED", "last_update": "2024-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02935634", "title": "A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2023-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02942329", "title": "Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer", "status": "UNKNOWN", "last_update": "2018-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02943603", "title": "A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach", "status": "WITHDRAWN", "last_update": "2018-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02946671", "title": "Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients", "status": "COMPLETED", "last_update": "2020-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02951091", "title": "Biomarker-Integrated Umbrella, Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2019-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954536", "title": "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer", "status": "COMPLETED", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02999295", "title": "A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer", "status": "COMPLETED", "last_update": "2019-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03006705", "title": "Study of Adjuvant ONO-4538 With Resected Gastric Cancer", "status": "COMPLETED", "last_update": "2024-05-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019588", "title": "Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)", "status": "TERMINATED", "last_update": "2023-03-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03043664", "title": "Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03044613", "title": "Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03044743", "title": "PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies", "status": "UNKNOWN", "last_update": "2017-05-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03064490", "title": "Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)", "status": "COMPLETED", "last_update": "2025-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03122548", "title": "Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers", "status": "TERMINATED", "last_update": "2019-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03172416", "title": "Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis", "status": "UNKNOWN", "last_update": "2024-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03196232", "title": "Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03221426", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)", "status": "COMPLETED", "last_update": "2026-03-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03236935", "title": "Phase Ib of L-NMMA and Pembrolizumab", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03257163", "title": "Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277352", "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies", "status": "TERMINATED", "last_update": "2021-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03321630", "title": "A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies", "status": "COMPLETED", "last_update": "2024-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03342417", "title": "Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients", "status": "TERMINATED", "last_update": "2021-11-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03342937", "title": "KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer", "status": "COMPLETED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03382600", "title": "Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)", "status": "COMPLETED", "last_update": "2024-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03393416", "title": "A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor", "status": "UNKNOWN", "last_update": "2019-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03395847", "title": "Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma", "status": "COMPLETED", "last_update": "2023-11-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03407976", "title": "Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies", "status": "TERMINATED", "last_update": "2020-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409848", "title": "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03443856", "title": "Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence", "status": "UNKNOWN", "last_update": "2024-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03453164", "title": "Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03469557", "title": "BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474640", "title": "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03488667", "title": "Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03511222", "title": "Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2020-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03554395", "title": "Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer", "status": "WITHDRAWN", "last_update": "2020-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03609359", "title": "Lenvatinib and Pembrolizumab Simultaneous Combination Study", "status": "COMPLETED", "last_update": "2025-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03615326", "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)", "status": "COMPLETED", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03621982", "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-06-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03647969", "title": "Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2024-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03662659", "title": "An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers", "status": "COMPLETED", "last_update": "2025-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03675737", "title": "Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03704077", "title": "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma", "status": "WITHDRAWN", "last_update": "2020-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03724851", "title": "Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer", "status": "COMPLETED", "last_update": "2025-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735290", "title": "A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer", "status": "TERMINATED", "last_update": "2022-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03755440", "title": "PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.", "status": "COMPLETED", "last_update": "2022-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03776487", "title": "Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03784040", "title": "Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.", "status": "UNKNOWN", "last_update": "2019-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03797326", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849469", "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03861793", "title": "A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)", "status": "COMPLETED", "last_update": "2024-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03872947", "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878472", "title": "Neoadjuvant Immunotherapy for Resectable Gastric Cancer", "status": "COMPLETED", "last_update": "2024-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03918499", "title": "IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2023-03-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03921021", "title": "Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2024-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03939962", "title": "Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma", "status": "UNKNOWN", "last_update": "2022-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03941873", "title": "A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2024-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03950271", "title": "SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03954756", "title": "Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2019-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03980925", "title": "Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.", "status": "COMPLETED", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03995017", "title": "Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma", "status": "UNKNOWN", "last_update": "2023-02-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007744", "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04032704", "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04041310", "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044859", "title": "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04062656", "title": "Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04069273", "title": "Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04082364", "title": "Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04099277", "title": "A Study of LY3435151 in Participants With Solid Tumors", "status": "TERMINATED", "last_update": "2021-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04099641", "title": "An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04130516", "title": "Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04139135", "title": "A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-06-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152018", "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.", "status": "TERMINATED", "last_update": "2025-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04164979", "title": "Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma", "status": "COMPLETED", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04174339", "title": "PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2019-11-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04180371", "title": "Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04187872", "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis", "status": "TERMINATED", "last_update": "2023-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04195373", "title": "A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract", "status": "WITHDRAWN", "last_update": "2020-11-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04196465", "title": "Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04208958", "title": "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-10-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209686", "title": "Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04234113", "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04249739", "title": "Pembrolizumab + Capecitabine\uff0fOxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive", "status": "UNKNOWN", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04250948", "title": "Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260802", "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04267549", "title": "Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04276493", "title": "Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04294784", "title": "Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04306900", "title": "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers", "status": "COMPLETED", "last_update": "2025-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04336098", "title": "Study of SRF617 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04344795", "title": "Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04363801", "title": "A Study of DKN-01 in Combination With Tislelizumab \u00b1 Chemotherapy in Patients With Gastric or Gastroesophageal Cancer", "status": "TERMINATED", "last_update": "2025-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04367025", "title": "Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer", "status": "UNKNOWN", "last_update": "2020-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04383938", "title": "Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2025-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04396821", "title": "A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "status": "UNKNOWN", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04486651", "title": "HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04503967", "title": "Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508140", "title": "Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis", "status": "TERMINATED", "last_update": "2024-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510064", "title": "Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma\uff1aFDZL-GC001 Trial", "status": "COMPLETED", "last_update": "2025-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "status": "TERMINATED", "last_update": "2023-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556253", "title": "AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04567069", "title": "Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment", "status": "UNKNOWN", "last_update": "2020-09-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579757", "title": "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04580485", "title": "INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04581473", "title": "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04594811", "title": "NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-08-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631731", "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity", "status": "UNKNOWN", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04632459", "title": "Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "status": "UNKNOWN", "last_update": "2024-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04682431", "title": "A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-03-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04694183", "title": "The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2024-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04727151", "title": "TAC T-cells for the Treatment of HER2-positive Solid Tumors", "status": "TERMINATED", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04744649", "title": "Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial", "status": "UNKNOWN", "last_update": "2022-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745988", "title": "An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04768686", "title": "FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2025-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04777162", "title": "Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer", "status": "UNKNOWN", "last_update": "2021-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04779151", "title": "Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab", "status": "TERMINATED", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04782791", "title": "Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04798781", "title": "Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04799548", "title": "A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma", "status": "UNKNOWN", "last_update": "2024-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802876", "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04819971", "title": "Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC", "status": "UNKNOWN", "last_update": "2023-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04847466", "title": "Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04859582", "title": "Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension", "status": "WITHDRAWN", "last_update": "2021-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04879368", "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC", "status": "COMPLETED", "last_update": "2026-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04882241", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension", "status": "COMPLETED", "last_update": "2026-03-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04886193", "title": "FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis", "status": "UNKNOWN", "last_update": "2021-05-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04889768", "title": "HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis", "status": "UNKNOWN", "last_update": "2021-05-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04890392", "title": "Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC", "status": "UNKNOWN", "last_update": "2021-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04913337", "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies", "status": "UNKNOWN", "last_update": "2024-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04931654", "title": "A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04963088", "title": "Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)", "status": "COMPLETED", "last_update": "2025-06-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05000554", "title": "The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer", "status": "UNKNOWN", "last_update": "2021-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05001360", "title": "Study of FMT Combined With Nivolumab in Gastric Cancer", "status": "WITHDRAWN", "last_update": "2021-10-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05025033", "title": "Chemotherapy Combined With Apatinib and PD-1 Antibody", "status": "COMPLETED", "last_update": "2023-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05029453", "title": "Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy", "status": "UNKNOWN", "last_update": "2021-08-31", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05039944", "title": "SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies", "status": "TERMINATED", "last_update": "2024-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05041153", "title": "Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05053295", "title": "Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-09-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05070247", "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05095636", "title": "Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05104567", "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)", "status": "COMPLETED", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05111626", "title": "Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.", "status": "TERMINATED", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05113459", "title": "Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer\uff08RC48-C018\uff09", "status": "UNKNOWN", "last_update": "2021-11-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05128487", "title": "A Study of NDI 1150-101 in Patients With Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05144854", "title": "A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-na\u00efve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05161572", "title": "Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer", "status": "TERMINATED", "last_update": "2025-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05162755", "title": "S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers", "status": "COMPLETED", "last_update": "2026-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05163483", "title": "Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05166577", "title": "Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC", "status": "TERMINATED", "last_update": "2025-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05173142", "title": "A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05180734", "title": "PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05184946", "title": "Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma", "status": "UNKNOWN", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05192460", "title": "Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer", "status": "UNKNOWN", "last_update": "2023-03-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05207722", "title": "CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-12-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215574", "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05223088", "title": "Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV\u3001Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05227378", "title": "Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-02-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238883", "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05246982", "title": "HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05262556", "title": "NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas", "status": "COMPLETED", "last_update": "2026-08-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05270824", "title": "Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2022-03-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05270889", "title": "Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial", "status": "UNKNOWN", "last_update": "2022-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311176", "title": "A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)", "status": "TERMINATED", "last_update": "2025-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311618", "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors", "status": "UNKNOWN", "last_update": "2024-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05322577", "title": "A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.", "status": "TERMINATED", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05325528", "title": "Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases", "status": "UNKNOWN", "last_update": "2023-02-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05329766", "title": "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342389", "title": "Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05379972", "title": "Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers", "status": "COMPLETED", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05385900", "title": "Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-05-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05438420", "title": "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05441254", "title": "Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis\uff1aSingle-arm, Prospective Clinical Study", "status": "UNKNOWN", "last_update": "2022-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05468138", "title": "PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05476796", "title": "Oxaliplatin \u00b1 Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05508737", "title": "Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05512182", "title": "Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression", "status": "WITHDRAWN", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05515796", "title": "Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors", "status": "COMPLETED", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05519202", "title": "Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05535569", "title": "Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2022-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05545436", "title": "Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568095", "title": "A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05572684", "title": "A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05586061", "title": "First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05594381", "title": "A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.", "status": "UNKNOWN", "last_update": "2022-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05608785", "title": "Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes", "status": "UNKNOWN", "last_update": "2022-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05620134", "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05632939", "title": "ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05648487", "title": "HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2022-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05708950", "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)", "status": "COMPLETED", "last_update": "2026-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05714553", "title": "NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours", "status": "TERMINATED", "last_update": "2026-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05721651", "title": "Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study", "status": "UNKNOWN", "last_update": "2023-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05739045", "title": "Nivolumab Combined With SOX Used in the Perioperative Treatment", "status": "UNKNOWN", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05745233", "title": "Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites", "status": "ENROLLING_BY_INVITATION", "last_update": "2023-08-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05751265", "title": "Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05788484", "title": "A Study of CDX-585 in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2025-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05789069", "title": "A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05802056", "title": "Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05858736", "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05859477", "title": "Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2024-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05860374", "title": "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2023-05-16", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867121", "title": "A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010", "status": "COMPLETED", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05886075", "title": "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2023-06-02", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05893056", "title": "Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)", "status": "UNKNOWN", "last_update": "2023-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05970627", "title": "Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05982301", "title": "Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05982834", "title": "Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC", "status": "UNKNOWN", "last_update": "2023-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05994456", "title": "Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008925", "title": "Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06036745", "title": "Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06093425", "title": "Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06098898", "title": "Safety and Efficacy of NK510 to Treat Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-10-25", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06109467", "title": "Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06116136", "title": "A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06131398", "title": "A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06197438", "title": "Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2024-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06202716", "title": "Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore", "status": "UNKNOWN", "last_update": "2024-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06238167", "title": "Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06238752", "title": "First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC", "status": "COMPLETED", "last_update": "2024-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06250036", "title": "Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer", "status": "SUSPENDED", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06251973", "title": "A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06256328", "title": "A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-na\u00efve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06266871", "title": "SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2024-02-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06349044", "title": "A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.", "status": "UNKNOWN", "last_update": "2024-08-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06374901", "title": "Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06487715", "title": "Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis", "status": "UNKNOWN", "last_update": "2024-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06544655", "title": "A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06576921", "title": "Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585488", "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification", "status": "TERMINATED", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06728657", "title": "Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma", "status": "SUSPENDED", "last_update": "2025-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06748508", "title": "Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06748872", "title": "EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764251", "title": "Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06871527", "title": "Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06888037", "title": "Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06914687", "title": "Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939439", "title": "Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06944496", "title": "A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957977", "title": "A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06963593", "title": "Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-09", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06980389", "title": "Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC)", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06992024", "title": "Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07031011", "title": "PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07050524", "title": "Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07068516", "title": "Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07132528", "title": "Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07139587", "title": "The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07149181", "title": "Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191405", "title": "Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218003", "title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07243938", "title": "Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07304258", "title": "A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score \u226410", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07315035", "title": "QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332533", "title": "A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07453875", "title": "LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07502027", "title": "A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07507526", "title": "A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07529613", "title": "Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2026-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07542262", "title": "Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07602140", "title": "TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07615907", "title": "A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07638631", "title": "Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07655661", "title": "Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07677293", "title": "Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07685704", "title": "Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07692334", "title": "Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07700979", "title": "Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770100", "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07788664", "title": "Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07801027", "title": "A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07807345", "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 8, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02757391", "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors", "status": "TERMINATED", "last_update": "2020-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02862028", "title": "PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)", "status": "UNKNOWN", "last_update": "2016-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04581473", "title": "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04727151", "title": "TAC T-cells for the Treatment of HER2-positive Solid Tumors", "status": "TERMINATED", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04847466", "title": "Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07031011", "title": "PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-1", "nivolumab", "pembrolizumab", "tislelizumab" ] }, "FGFR2b": { "n": 22, "n_observational": 1, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT06632262", "title": "A Phase 2 Clinical Study of ABSK061 and ABSK043", "status": "RECRUITING", "last_update": "2024-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07354711", "title": "A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00979134", "title": "Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours", "status": "TERMINATED", "last_update": "2019-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01457846", "title": "Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer", "status": "TERMINATED", "last_update": "2017-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01719549", "title": "Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1", "status": "COMPLETED", "last_update": "2020-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01795768", "title": "Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours", "status": "UNKNOWN", "last_update": "2013-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02052778", "title": "A Study of TAS-120 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318329", "title": "Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03343301", "title": "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2024-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03694522", "title": "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04071184", "title": "Study of Alofanib in Patients With Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2019-09-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04189445", "title": "Futibatinib in Patients With Specific FGFR Aberrations", "status": "TERMINATED", "last_update": "2025-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04604132", "title": "Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05019794", "title": "Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations", "status": "UNKNOWN", "last_update": "2022-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05052801", "title": "Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression", "status": "COMPLETED", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05111626", "title": "Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.", "status": "TERMINATED", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05322577", "title": "A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.", "status": "TERMINATED", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05859477", "title": "Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2024-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05913115", "title": "A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06206278", "title": "Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06967987", "title": "Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b", "status": "WITHDRAWN", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "FGFR2b", "FGFR2", "bemarituzumab" ] }, "VEGFR2": { "n": 69, "n_observational": 12, "n_active": 23, "n_withdrawn": 3, "trials": [ { "nct": "NCT04660760", "title": "Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer", "status": "RECRUITING", "last_update": "2024-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04999761", "title": "AB122 Platform Study", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05365581", "title": "A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05894824", "title": "T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma", "status": "RECRUITING", "last_update": "2025-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05927857", "title": "Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06038578", "title": "A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123494", "title": "SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen", "status": "RECRUITING", "last_update": "2024-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06203600", "title": "Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06675136", "title": "Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases", "status": "RECRUITING", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773312", "title": "BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.", "status": "RECRUITING", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06962137", "title": "Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer", "status": "RECRUITING", "last_update": "2025-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00681252", "title": "Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer", "status": "COMPLETED", "last_update": "2009-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00681577", "title": "Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer", "status": "COMPLETED", "last_update": "2009-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00917384", "title": "Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma", "status": "COMPLETED", "last_update": "2019-09-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01170663", "title": "A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2019-09-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01246960", "title": "A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2014-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01253525", "title": "Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas", "status": "COMPLETED", "last_update": "2014-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01983878", "title": "A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2019-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02082210", "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314117", "title": "A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer", "status": "COMPLETED", "last_update": "2021-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02359058", "title": "A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer", "status": "COMPLETED", "last_update": "2018-01-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02443324", "title": "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer", "status": "COMPLETED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02443883", "title": "A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer", "status": "COMPLETED", "last_update": "2020-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02514551", "title": "A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer", "status": "COMPLETED", "last_update": "2020-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02572687", "title": "A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies", "status": "COMPLETED", "last_update": "2021-01-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02661971", "title": "FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)", "status": "COMPLETED", "last_update": "2022-07-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02678182", "title": "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02726399", "title": "Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer", "status": "TERMINATED", "last_update": "2020-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02898077", "title": "A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2022-06-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02934464", "title": "Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers", "status": "UNKNOWN", "last_update": "2021-09-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02970539", "title": "Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers", "status": "UNKNOWN", "last_update": "2022-02-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02999295", "title": "A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer", "status": "COMPLETED", "last_update": "2019-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03008278", "title": "Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2026-02-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03030937", "title": "Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA", "status": "UNKNOWN", "last_update": "2017-01-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03081143", "title": "Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy", "status": "COMPLETED", "last_update": "2026-07-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03281369", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03686488", "title": "TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma", "status": "COMPLETED", "last_update": "2026-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03704077", "title": "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma", "status": "WITHDRAWN", "last_update": "2020-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03739801", "title": "MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma", "status": "WITHDRAWN", "last_update": "2020-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03760822", "title": "Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients", "status": "UNKNOWN", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766607", "title": "Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer", "status": "WITHDRAWN", "last_update": "2019-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03797326", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03872947", "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03966118", "title": "Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma", "status": "UNKNOWN", "last_update": "2019-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03995017", "title": "Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma", "status": "UNKNOWN", "last_update": "2023-02-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04069273", "title": "Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2025-01-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04604132", "title": "Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04632459", "title": "Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04656002", "title": "As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers", "status": "UNKNOWN", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704934", "title": "Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04888663", "title": "Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)", "status": "UNKNOWN", "last_update": "2021-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05002127", "title": "A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05071053", "title": "Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer", "status": "TERMINATED", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05190445", "title": "Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311176", "title": "A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)", "status": "TERMINATED", "last_update": "2025-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05800418", "title": "Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza \u00ae in Healthy Male Volunteers", "status": "COMPLETED", "last_update": "2023-04-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05942573", "title": "Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial", "status": "UNKNOWN", "last_update": "2023-07-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05980416", "title": "Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2", "status": "TERMINATED", "last_update": "2025-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06169410", "title": "Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2024-01-23", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06251973", "title": "A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06346392", "title": "AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06564298", "title": "A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis", "status": "UNKNOWN", "last_update": "2024-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06904300", "title": "Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07594548", "title": "Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07669740", "title": "A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "VEGFR2", "ramucirumab" ] }, "CEA": { "n": 30, "n_observational": 4, "n_active": 7, "n_withdrawn": 4, "trials": [ { "nct": "NCT06010862", "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043466", "title": "A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06126406", "title": "Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes\uff08CAR-T\uff09 for CEA Positive Advanced Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06821048", "title": "Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2026-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07179692", "title": "CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003125", "title": "Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors", "status": "COMPLETED", "last_update": "2011-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004604", "title": "Biological Therapy in Treating Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012246", "title": "Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract", "status": "TERMINATED", "last_update": "2013-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00027534", "title": "Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2014-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00028496", "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00429078", "title": "Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer", "status": "WITHDRAWN", "last_update": "2012-03-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00834236", "title": "Proteiomic Fingerprints of Gastric Juice", "status": "COMPLETED", "last_update": "2015-12-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01212887", "title": "Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer", "status": "TERMINATED", "last_update": "2012-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01637805", "title": "Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer", "status": "UNKNOWN", "last_update": "2016-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01723306", "title": "Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas", "status": "SUSPENDED", "last_update": "2016-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02346955", "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)", "status": "TERMINATED", "last_update": "2020-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02349724", "title": "A Clinical Research of CAR T Cells Targeting CEA Positive Cancer", "status": "UNKNOWN", "last_update": "2017-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02416466", "title": "CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases", "status": "COMPLETED", "last_update": "2019-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02496273", "title": "Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2016-02-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02850536", "title": "CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer", "status": "COMPLETED", "last_update": "2021-10-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03682744", "title": "CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)", "status": "WITHDRAWN", "last_update": "2022-04-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03957564", "title": "Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer", "status": "UNKNOWN", "last_update": "2020-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04348643", "title": "Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer", "status": "WITHDRAWN", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05071053", "title": "Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer", "status": "TERMINATED", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05396300", "title": "A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05415475", "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05538195", "title": "Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05703555", "title": "INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701", "status": "WITHDRAWN", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06006390", "title": "CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06710132", "title": "Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 16, "n_observational": 0, "n_active": 5, "n_withdrawn": 3, "trials": [ { "nct": "NCT06010862", "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043466", "title": "A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06126406", "title": "Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes\uff08CAR-T\uff09 for CEA Positive Advanced Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06821048", "title": "Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2026-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07179692", "title": "CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00429078", "title": "Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer", "status": "WITHDRAWN", "last_update": "2012-03-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01723306", "title": "Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas", "status": "SUSPENDED", "last_update": "2016-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02349724", "title": "A Clinical Research of CAR T Cells Targeting CEA Positive Cancer", "status": "UNKNOWN", "last_update": "2017-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02416466", "title": "CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases", "status": "COMPLETED", "last_update": "2019-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02850536", "title": "CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer", "status": "COMPLETED", "last_update": "2021-10-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03682744", "title": "CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)", "status": "WITHDRAWN", "last_update": "2022-04-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04348643", "title": "Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer", "status": "WITHDRAWN", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05396300", "title": "A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05415475", "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05538195", "title": "Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06006390", "title": "CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CEA", "CEACAM5" ] }, "TROP2": { "n": 15, "n_observational": 0, "n_active": 14, "n_withdrawn": 0, "trials": [ { "nct": "NCT05489211", "title": "Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941507", "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05969041", "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06065371", "title": "Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06602037", "title": "ImmunoPET Imaging of Pancreatic Cancer", "status": "RECRUITING", "last_update": "2025-12-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06715839", "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01631552", "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer", "status": "COMPLETED", "last_update": "2021-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152499", "title": "Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05460273", "title": "A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06356311", "title": "A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07509008", "title": "Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07689292", "title": "Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07701681", "title": "Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07509008", "title": "Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "TROP2", "TACSTD2", "sacituzumab" ] } }, "by_drug": { "ADAGRASIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT05848843", "title": "A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ADEBRELIMAB": { "n": 17, "n_observational": 2, "n_active": 16, "n_withdrawn": 0, "trials": [ { "nct": "NCT06415669", "title": "A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "RECRUITING", "last_update": "2024-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06506292", "title": "A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)", "status": "RECRUITING", "last_update": "2024-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06776770", "title": "A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer", "status": "RECRUITING", "last_update": "2025-01-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07110571", "title": "A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07309185", "title": "Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07353684", "title": "Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07522151", "title": "Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770113", "title": "A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel \u00b1 Adebrelimab in Treating Advanced Second-line Gastric Cancer", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06247956", "title": "Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06339216", "title": "A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06385873", "title": "RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475417", "title": "Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer", "status": "UNKNOWN", "last_update": "2024-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06592287", "title": "The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06881017", "title": "Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07033143", "title": "Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07266025", "title": "Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma\uff1aA Randomized, Non-comparative Phase 2 Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07314203", "title": "Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB": { "n": 8, "n_observational": 0, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT06085755", "title": "Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01649271", "title": "Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.", "status": "COMPLETED", "last_update": "2025-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01743365", "title": "Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer", "status": "COMPLETED", "last_update": "2019-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274012", "title": "Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment", "status": "WITHDRAWN", "last_update": "2017-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02501603", "title": "Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2023-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02951091", "title": "Biomarker-Integrated Umbrella, Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB DIMALEATE": { "n": 8, "n_observational": 0, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT06085755", "title": "Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01649271", "title": "Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.", "status": "COMPLETED", "last_update": "2025-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01743365", "title": "Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer", "status": "COMPLETED", "last_update": "2019-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274012", "title": "Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment", "status": "WITHDRAWN", "last_update": "2017-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02501603", "title": "Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2023-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02951091", "title": "Biomarker-Integrated Umbrella, Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "ALPELISIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01613950", "title": "PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04526470", "title": "Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AMG-337": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT02016534", "title": "Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors", "status": "TERMINATED", "last_update": "2017-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02096666", "title": "A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects", "status": "COMPLETED", "last_update": "2021-12-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02344810", "title": "C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer", "status": "WITHDRAWN", "last_update": "2023-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AMIVANTAMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04945733", "title": "A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ATEZOLIZUMAB": { "n": 36, "n_observational": 0, "n_active": 13, "n_withdrawn": 3, "trials": [ { "nct": "NCT05482516", "title": "Evaluating Novel Therapies in ctDNA Positive GI Cancers", "status": "RECRUITING", "last_update": "2025-05-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06819566", "title": "Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC", "status": "RECRUITING", "last_update": "2025-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06961526", "title": "Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab", "status": "RECRUITING", "last_update": "2025-05-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02876510", "title": "ACTolog in Patients With Solid Cancers", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03281369", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399071", "title": "Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03421288", "title": "Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03448835", "title": "Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03650348", "title": "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818997", "title": "Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer", "status": "WITHDRAWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829501", "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03982173", "title": "Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors", "status": "WITHDRAWN", "last_update": "2023-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04166721", "title": "WaKING: Wnt and checKpoint INhibition in Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04604132", "title": "Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631731", "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity", "status": "UNKNOWN", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04661150", "title": "A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction", "status": "COMPLETED", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04713891", "title": "A Study of KF-0210 in Advanced Solid Tumors Patients", "status": "COMPLETED", "last_update": "2024-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04739202", "title": "Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)", "status": "COMPLETED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04933227", "title": "A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)", "status": "TERMINATED", "last_update": "2024-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05253053", "title": "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05411133", "title": "Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients", "status": "COMPLETED", "last_update": "2026-03-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05836584", "title": "Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867121", "title": "A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010", "status": "COMPLETED", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06090318", "title": "Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss", "status": "WITHDRAWN", "last_update": "2023-10-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06098898", "title": "Safety and Efficacy of NK510 to Treat Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-10-25", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770100", "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AVELUMAB": { "n": 15, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01943461", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)", "status": "COMPLETED", "last_update": "2020-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "status": "TERMINATED", "last_update": "2024-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625610", "title": "Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)", "status": "COMPLETED", "last_update": "2022-06-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625623", "title": "Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)", "status": "COMPLETED", "last_update": "2020-11-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399071", "title": "Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03475953", "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors", "status": "UNKNOWN", "last_update": "2023-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03783936", "title": "Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03966118", "title": "Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma", "status": "UNKNOWN", "last_update": "2019-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03979131", "title": "Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260802", "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05419362", "title": "GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer", "status": "COMPLETED", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AXITINIB": { "n": 2, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00842244", "title": "Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2013-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04458259", "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.", "status": "TERMINATED", "last_update": "2026-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BEMARITUZUMAB": { "n": 9, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318329", "title": "Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03343301", "title": "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2024-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03694522", "title": "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05052801", "title": "Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression", "status": "COMPLETED", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05111626", "title": "Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.", "status": "TERMINATED", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05322577", "title": "A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.", "status": "TERMINATED", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05913115", "title": "A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06967987", "title": "Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b", "status": "WITHDRAWN", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BINTRAFUSP ALFA": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04835896", "title": "Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2024-05-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BRIVANIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00633789", "title": "Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types", "status": "COMPLETED", "last_update": "2015-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01046864", "title": "Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)", "status": "COMPLETED", "last_update": "2014-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BRIVANIB ALANINATE": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00633789", "title": "Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types", "status": "COMPLETED", "last_update": "2015-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01046864", "title": "Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)", "status": "COMPLETED", "last_update": "2014-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BUPARLISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01576666", "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CABOZANTINIB": { "n": 5, "n_observational": 1, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT03539822", "title": "Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04893785", "title": "A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)", "status": "RECRUITING", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00940225", "title": "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04164979", "title": "Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma", "status": "COMPLETED", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CAPMATINIB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06988475", "title": "DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01324479", "title": "Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CATEQUENTINIB": { "n": 14, "n_observational": 1, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT05494060", "title": "XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma", "status": "RECRUITING", "last_update": "2023-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02461407", "title": "Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)", "status": "UNKNOWN", "last_update": "2017-12-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278222", "title": "Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)", "status": "UNKNOWN", "last_update": "2024-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04503967", "title": "Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04764084", "title": "Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2021-02-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04777162", "title": "Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer", "status": "UNKNOWN", "last_update": "2021-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04891900", "title": "TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "UNKNOWN", "last_update": "2024-07-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04963088", "title": "Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)", "status": "COMPLETED", "last_update": "2025-06-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05029102", "title": "TAS-102 and Anlotinib in \u22653 Lines mGC", "status": "UNKNOWN", "last_update": "2024-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05385900", "title": "Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-05-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05608785", "title": "Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes", "status": "UNKNOWN", "last_update": "2022-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05800080", "title": "An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC", "status": "UNKNOWN", "last_update": "2023-04-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06222944", "title": "Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA", "status": "UNKNOWN", "last_update": "2024-01-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939452", "title": "A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CEDIRANIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00385203", "title": "The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).", "status": "COMPLETED", "last_update": "2012-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00475956", "title": "Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2010-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00960349", "title": "Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients", "status": "COMPLETED", "last_update": "2011-06-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CEP-11981": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05988918", "title": "Multicenter Trial of ESK981 in Patients With Select Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CM-082": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03286244", "title": "Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2019-02-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CONTUSUGENE LADENOVEC": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "COPANLISIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CRIZOTINIB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02435108", "title": "A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy", "status": "COMPLETED", "last_update": "2017-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03620643", "title": "Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours", "status": "COMPLETED", "last_update": "2025-10-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CUDC-101": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01171924", "title": "A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors", "status": "COMPLETED", "last_update": "2016-03-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DACOMITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01152853", "title": "PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer", "status": "COMPLETED", "last_update": "2015-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DERAZANTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04604132", "title": "Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DISITAMAB VEDOTIN": { "n": 28, "n_observational": 1, "n_active": 19, "n_withdrawn": 0, "trials": [ { "nct": "NCT06155383", "title": "Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.", "status": "RECRUITING", "last_update": "2023-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06221748", "title": "DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy", "status": "RECRUITING", "last_update": "2024-04-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06487429", "title": "Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer", "status": "RECRUITING", "last_update": "2024-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06560528", "title": "Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression", "status": "RECRUITING", "last_update": "2024-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06572319", "title": "Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens", "status": "RECRUITING", "last_update": "2024-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06650332", "title": "Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients", "status": "RECRUITING", "last_update": "2024-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06730373", "title": "First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)", "status": "RECRUITING", "last_update": "2024-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07194005", "title": "Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer", "status": "RECRUITING", "last_update": "2025-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07315750", "title": "A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07474324", "title": "Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage \u2162 Gastric Cancer: A Prospective, Multicenter, Randomized, Phase \u2161 Clinical Trial", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05113459", "title": "Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer\uff08RC48-C018\uff09", "status": "UNKNOWN", "last_update": "2021-11-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05313906", "title": "RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05514158", "title": "To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)", "status": "UNKNOWN", "last_update": "2023-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05586061", "title": "First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05627414", "title": "Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05720533", "title": "Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05928897", "title": "Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab", "status": "UNKNOWN", "last_update": "2023-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05980481", "title": "A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05982834", "title": "Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC", "status": "UNKNOWN", "last_update": "2023-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06078982", "title": "Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06157892", "title": "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06227325", "title": "Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression", "status": "UNKNOWN", "last_update": "2024-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06385873", "title": "RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06492317", "title": "RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06944496", "title": "A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07490990", "title": "Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07507526", "title": "A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07602140", "title": "TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DOVITINIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01576380", "title": "A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients", "status": "COMPLETED", "last_update": "2017-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01719549", "title": "Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1", "status": "COMPLETED", "last_update": "2020-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01921673", "title": "Dovitinib Plus Docetaxel in Gastric Cancer", "status": "COMPLETED", "last_update": "2017-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DURVALUMAB": { "n": 30, "n_observational": 1, "n_active": 18, "n_withdrawn": 2, "trials": [ { "nct": "NCT03539822", "title": "Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04900818", "title": "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187338", "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05620628", "title": "Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06630130", "title": "Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06824363", "title": "ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07700420", "title": "Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264678", "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02572687", "title": "A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies", "status": "COMPLETED", "last_update": "2021-01-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658214", "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02678182", "title": "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02734004", "title": "A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03579784", "title": "Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer", "status": "UNKNOWN", "last_update": "2024-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03751761", "title": "GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study", "status": "COMPLETED", "last_update": "2024-02-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03780608", "title": "This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)", "status": "UNKNOWN", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03959293", "title": "Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma", "status": "UNKNOWN", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03982173", "title": "Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors", "status": "WITHDRAWN", "last_update": "2023-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04078152", "title": "Durvalumab Long-Term Safety and Efficacy Study", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04592913", "title": "Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631731", "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity", "status": "UNKNOWN", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04817826", "title": "TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04893252", "title": "Vactosertib and Durvalumab in Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05034887", "title": "Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05713838", "title": "Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05848843", "title": "A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07565857", "title": "Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07757191", "title": "DURATION-GC: FLOT Plus Durvalumab and TS-1 Plus Durvalumab for Resectable Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EMIBETUZUMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01874938", "title": "A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2015-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02082210", "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENVAFOLIMAB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06791083", "title": "Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer", "status": "RECRUITING", "last_update": "2025-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05237349", "title": "Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma", "status": "UNKNOWN", "last_update": "2024-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EPRENETAPOPT": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02999893", "title": "A Study of APR-246 in Oesophageal Cancer", "status": "TERMINATED", "last_update": "2021-12-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04383938", "title": "Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2025-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ERDAFITINIB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02699606", "title": "A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma", "status": "COMPLETED", "last_update": "2025-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FAMITINIB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07309185", "title": "Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01994213", "title": "A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor", "status": "TERMINATED", "last_update": "2019-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FEXAGRATINIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FORETINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00725712", "title": "Study of GSK1363089 in Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2017-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FRUQUINTINIB": { "n": 29, "n_observational": 7, "n_active": 18, "n_withdrawn": 0, "trials": [ { "nct": "NCT06091423", "title": "XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study", "status": "RECRUITING", "last_update": "2023-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06158919", "title": "A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer", "status": "RECRUITING", "last_update": "2023-12-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06774222", "title": "A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG", "status": "RECRUITING", "last_update": "2025-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06791083", "title": "Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer", "status": "RECRUITING", "last_update": "2025-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07270991", "title": "Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-02-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07334431", "title": "Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392346", "title": "Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07552402", "title": "Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02415023", "title": "A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03223376", "title": "A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)", "status": "COMPLETED", "last_update": "2025-12-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05024812", "title": "Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "UNKNOWN", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05122091", "title": "Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma", "status": "UNKNOWN", "last_update": "2024-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05177068", "title": "Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05241899", "title": "A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer", "status": "UNKNOWN", "last_update": "2022-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05625737", "title": "Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma", "status": "UNKNOWN", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05643677", "title": "Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05721651", "title": "Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study", "status": "UNKNOWN", "last_update": "2023-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05795296", "title": "Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-08-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05914610", "title": "Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05982834", "title": "Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC", "status": "UNKNOWN", "last_update": "2023-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06078670", "title": "PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2023-10-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06094868", "title": "Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06454435", "title": "Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06706895", "title": "A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06871527", "title": "Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06888037", "title": "Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06977061", "title": "Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07658872", "title": "Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07689292", "title": "Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FUTIBATINIB": { "n": 4, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT04999761", "title": "AB122 Platform Study", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02052778", "title": "A Study of TAS-120 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04189445", "title": "Futibatinib in Patients With Specific FGFR Aberrations", "status": "TERMINATED", "last_update": "2025-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07594548", "title": "Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "HMPL-453": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT05173142", "title": "A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "INFIGRATINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT05019794", "title": "Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations", "status": "UNKNOWN", "last_update": "2022-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06206278", "title": "Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "KBP5209": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02442414", "title": "A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "KN-026": { "n": 7, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05427383", "title": "KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy", "status": "RECRUITING", "last_update": "2023-12-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06023758", "title": "Phase 2 Trial of KN026+KN046\u00b1XELOX in HER2-positive Locally Advanced GC", "status": "RECRUITING", "last_update": "2024-05-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03619681", "title": "Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer", "status": "COMPLETED", "last_update": "2024-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03847168", "title": "KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03925974", "title": "KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998771", "title": "JSKN003 Combined Treatment of HER2-positive Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332533", "title": "A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB": { "n": 13, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00103324", "title": "S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer", "status": "COMPLETED", "last_update": "2013-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00259987", "title": "Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus", "status": "COMPLETED", "last_update": "2009-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00450203", "title": "Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer", "status": "UNKNOWN", "last_update": "2016-12-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00486954", "title": "Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2013-06-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00526669", "title": "Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib", "status": "COMPLETED", "last_update": "2016-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00680901", "title": "LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01123473", "title": "Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer", "status": "TERMINATED", "last_update": "2016-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01145404", "title": "Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer", "status": "TERMINATED", "last_update": "2014-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02015169", "title": "Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis", "status": "COMPLETED", "last_update": "2018-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB DITOSYLATE": { "n": 13, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00103324", "title": "S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer", "status": "COMPLETED", "last_update": "2013-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00259987", "title": "Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus", "status": "COMPLETED", "last_update": "2009-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00450203", "title": "Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer", "status": "UNKNOWN", "last_update": "2016-12-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00486954", "title": "Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2013-06-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00526669", "title": "Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib", "status": "COMPLETED", "last_update": "2016-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00680901", "title": "LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01123473", "title": "Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer", "status": "TERMINATED", "last_update": "2016-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01145404", "title": "Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer", "status": "TERMINATED", "last_update": "2014-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02015169", "title": "Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis", "status": "COMPLETED", "last_update": "2018-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LENVATINIB": { "n": 22, "n_observational": 0, "n_active": 12, "n_withdrawn": 0, "trials": [ { "nct": "NCT04519151", "title": "Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer", "status": "RECRUITING", "last_update": "2023-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06157996", "title": "Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore", "status": "RECRUITING", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06277024", "title": "A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients", "status": "RECRUITING", "last_update": "2024-02-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06580574", "title": "Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07149090", "title": "Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites", "status": "RECRUITING", "last_update": "2025-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03321630", "title": "A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies", "status": "COMPLETED", "last_update": "2024-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03609359", "title": "Lenvatinib and Pembrolizumab Simultaneous Combination Study", "status": "COMPLETED", "last_update": "2025-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03797326", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04193553", "title": "Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure", "status": "COMPLETED", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745988", "title": "An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05041153", "title": "Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05171530", "title": "Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05221775", "title": "Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients", "status": "UNKNOWN", "last_update": "2022-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05585580", "title": "Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05620134", "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05893056", "title": "Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)", "status": "UNKNOWN", "last_update": "2023-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06202716", "title": "Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore", "status": "UNKNOWN", "last_update": "2024-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06383559", "title": "Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients", "status": "UNKNOWN", "last_update": "2024-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06499610", "title": "Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-12", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06748508", "title": "Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07356466", "title": "Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-01-21", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "LUCITANIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03260179", "title": "Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810", "status": "UNKNOWN", "last_update": "2017-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MARGETUXIMAB": { "n": 4, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01148849", "title": "Safety Study of MGAH22 in HER2-positive Carcinomas", "status": "COMPLETED", "last_update": "2025-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689284", "title": "Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04082364", "title": "Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "MM-111": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01774851", "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach", "status": "TERMINATED", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NERATINIB": { "n": 5, "n_observational": 0, "n_active": 4, "n_withdrawn": 1, "trials": [ { "nct": "NCT05274048", "title": "Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients", "status": "RECRUITING", "last_update": "2025-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05512182", "title": "Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression", "status": "WITHDRAWN", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06109467", "title": "Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06374888", "title": "Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OMIPALISIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ONARTUZUMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01590719", "title": "A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2016-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01662869", "title": "A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ORANTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00024063", "title": "SU006668 in Treating Patients With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2013-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PAZOPANIB": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00454363", "title": "Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer", "status": "COMPLETED", "last_update": "2020-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130805", "title": "A Study of Pazopanib With CAPEOX in AGC Patients", "status": "COMPLETED", "last_update": "2016-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01503372", "title": "FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2019-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01716546", "title": "Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer", "status": "TERMINATED", "last_update": "2015-10-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PEMIGATINIB": { "n": 5, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02393248", "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)", "status": "TERMINATED", "last_update": "2023-01-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05202236", "title": "A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy", "status": "UNKNOWN", "last_update": "2022-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05529667", "title": "Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.", "status": "COMPLETED", "last_update": "2024-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05997459", "title": "A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant", "status": "UNKNOWN", "last_update": "2023-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06551896", "title": "Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PERTUZUMAB": { "n": 8, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05150691", "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01461057", "title": "A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01774786", "title": "A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer", "status": "COMPLETED", "last_update": "2020-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205047", "title": "Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02581462", "title": "FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer", "status": "COMPLETED", "last_update": "2020-08-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06136897", "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "POZIOTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01746771", "title": "A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2016-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PYROTINIB": { "n": 5, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02378389", "title": "Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2015-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02500199", "title": "Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors", "status": "UNKNOWN", "last_update": "2021-02-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03480256", "title": "Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer", "status": "UNKNOWN", "last_update": "2019-03-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05070598", "title": "Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05111444", "title": "Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma", "status": "UNKNOWN", "last_update": "2021-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "RAMUCIRUMAB": { "n": 63, "n_observational": 11, "n_active": 21, "n_withdrawn": 3, "trials": [ { "nct": "NCT04660760", "title": "Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer", "status": "RECRUITING", "last_update": "2024-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04999761", "title": "AB122 Platform Study", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05365581", "title": "A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05894824", "title": "T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma", "status": "RECRUITING", "last_update": "2025-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05927857", "title": "Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06038578", "title": "A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123494", "title": "SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen", "status": "RECRUITING", "last_update": "2024-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06203600", "title": "Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06675136", "title": "Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases", "status": "RECRUITING", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06962137", "title": "Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer", "status": "RECRUITING", "last_update": "2025-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00917384", "title": "Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma", "status": "COMPLETED", "last_update": "2019-09-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01170663", "title": "A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2019-09-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01246960", "title": "A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2014-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01253525", "title": "Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas", "status": "COMPLETED", "last_update": "2014-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01983878", "title": "A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2019-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02082210", "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314117", "title": "A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer", "status": "COMPLETED", "last_update": "2021-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02359058", "title": "A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer", "status": "COMPLETED", "last_update": "2018-01-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02443324", "title": "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer", "status": "COMPLETED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02443883", "title": "A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer", "status": "COMPLETED", "last_update": "2020-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02514551", "title": "A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer", "status": "COMPLETED", "last_update": "2020-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02572687", "title": "A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies", "status": "COMPLETED", "last_update": "2021-01-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02661971", "title": "FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)", "status": "COMPLETED", "last_update": "2022-07-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02678182", "title": "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02726399", "title": "Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer", "status": "TERMINATED", "last_update": "2020-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02898077", "title": "A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2022-06-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02934464", "title": "Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers", "status": "UNKNOWN", "last_update": "2021-09-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02970539", "title": "Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers", "status": "UNKNOWN", "last_update": "2022-02-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02999295", "title": "A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer", "status": "COMPLETED", "last_update": "2019-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03008278", "title": "Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2026-02-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03081143", "title": "Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy", "status": "COMPLETED", "last_update": "2026-07-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03281369", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03686488", "title": "TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma", "status": "COMPLETED", "last_update": "2026-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03704077", "title": "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma", "status": "WITHDRAWN", "last_update": "2020-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03739801", "title": "MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma", "status": "WITHDRAWN", "last_update": "2020-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03760822", "title": "Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients", "status": "UNKNOWN", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766607", "title": "Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer", "status": "WITHDRAWN", "last_update": "2019-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03872947", "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03966118", "title": "Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma", "status": "UNKNOWN", "last_update": "2019-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03995017", "title": "Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma", "status": "UNKNOWN", "last_update": "2023-02-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04069273", "title": "Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2025-01-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04604132", "title": "Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04632459", "title": "Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04656002", "title": "As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers", "status": "UNKNOWN", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704934", "title": "Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04888663", "title": "Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)", "status": "UNKNOWN", "last_update": "2021-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05002127", "title": "A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05071053", "title": "Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer", "status": "TERMINATED", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05190445", "title": "Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311176", "title": "A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)", "status": "TERMINATED", "last_update": "2025-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05800418", "title": "Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza \u00ae in Healthy Male Volunteers", "status": "COMPLETED", "last_update": "2023-04-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05942573", "title": "Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial", "status": "UNKNOWN", "last_update": "2023-07-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05980416", "title": "Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2", "status": "TERMINATED", "last_update": "2025-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06169410", "title": "Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2024-01-23", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06251973", "title": "A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06346392", "title": "AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06564298", "title": "A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis", "status": "UNKNOWN", "last_update": "2024-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06904300", "title": "Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07594548", "title": "Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07669740", "title": "A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "REGORAFENIB": { "n": 10, "n_observational": 1, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01913639", "title": "FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2020-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02241720", "title": "Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers", "status": "TERMINATED", "last_update": "2018-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02406170", "title": "Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma", "status": "COMPLETED", "last_update": "2019-10-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02773524", "title": "A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer", "status": "UNKNOWN", "last_update": "2022-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03475953", "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors", "status": "UNKNOWN", "last_update": "2023-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03627728", "title": "Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2025-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03722108", "title": "Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas", "status": "TERMINATED", "last_update": "2023-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03890731", "title": "A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed", "status": "COMPLETED", "last_update": "2024-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04879368", "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC", "status": "COMPLETED", "last_update": "2026-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "RIVOCERANIB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07311408", "title": "SHR-1701 + Rivoceranib (\u00b1 SHR-2554) in Advanced GC After First-Line Immunotherapy Failure", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03042611", "title": "A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer", "status": "COMPLETED", "last_update": "2022-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03707028", "title": "A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer", "status": "TERMINATED", "last_update": "2022-04-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ROGARATINIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04595747", "title": "Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SAPITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01579578", "title": "Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer", "status": "TERMINATED", "last_update": "2014-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SAVOLITINIB": { "n": 4, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05620628", "title": "Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02252913", "title": "A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2016-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02447406", "title": "Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment", "status": "COMPLETED", "last_update": "2022-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04923932", "title": "Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients", "status": "COMPLETED", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SERABELISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02625259", "title": "A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants", "status": "COMPLETED", "last_update": "2018-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SORAFENIB": { "n": 8, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00253370", "title": "Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2014-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00565370", "title": "Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP", "status": "COMPLETED", "last_update": "2020-01-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00595985", "title": "Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer", "status": "TERMINATED", "last_update": "2009-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00663741", "title": "Sorafenib Gastric Cancer Asian Phase I Study", "status": "COMPLETED", "last_update": "2013-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01158287", "title": "Sorafenib. ICORG 06-41, V4", "status": "COMPLETED", "last_update": "2014-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01183663", "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)", "status": "COMPLETED", "last_update": "2016-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01187212", "title": "Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE", "status": "COMPLETED", "last_update": "2020-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01262482", "title": "Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment", "status": "COMPLETED", "last_update": "2012-11-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SUNITINIB": { "n": 17, "n_observational": 2, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT04893785", "title": "A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)", "status": "RECRUITING", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05477576", "title": "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00226811", "title": "An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy", "status": "COMPLETED", "last_update": "2015-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00411151", "title": "Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2011-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00428220", "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.", "status": "COMPLETED", "last_update": "2019-06-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00524186", "title": "Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer", "status": "TERMINATED", "last_update": "2016-06-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553696", "title": "Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer", "status": "COMPLETED", "last_update": "2015-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00555620", "title": "Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2013-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00555672", "title": "Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2011-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01020630", "title": "Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI", "status": "COMPLETED", "last_update": "2014-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01054911", "title": "Evaluation of Patients With Bulky GIST Using Sunitinib", "status": "TERMINATED", "last_update": "2016-09-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01238055", "title": "Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer", "status": "COMPLETED", "last_update": "2013-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01506336", "title": "Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib", "status": "COMPLETED", "last_update": "2018-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01803503", "title": "Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170180", "title": "Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04193553", "title": "Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure", "status": "COMPLETED", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SUNITINIB MALATE": { "n": 17, "n_observational": 2, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT04893785", "title": "A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)", "status": "RECRUITING", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05477576", "title": "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00226811", "title": "An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy", "status": "COMPLETED", "last_update": "2015-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00411151", "title": "Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2011-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00428220", "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.", "status": "COMPLETED", "last_update": "2019-06-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00524186", "title": "Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer", "status": "TERMINATED", "last_update": "2016-06-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553696", "title": "Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer", "status": "COMPLETED", "last_update": "2015-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00555620", "title": "Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2013-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00555672", "title": "Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2011-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01020630", "title": "Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI", "status": "COMPLETED", "last_update": "2014-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01054911", "title": "Evaluation of Patients With Bulky GIST Using Sunitinib", "status": "TERMINATED", "last_update": "2016-09-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01238055", "title": "Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer", "status": "COMPLETED", "last_update": "2013-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01506336", "title": "Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib", "status": "COMPLETED", "last_update": "2018-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01803503", "title": "Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170180", "title": "Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04193553", "title": "Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure", "status": "COMPLETED", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SURUFATINIB": { "n": 5, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT04579757", "title": "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05235906", "title": "A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05527821", "title": "Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2022-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06447636", "title": "Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06531291", "title": "Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TAS-115": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04999761", "title": "AB122 Platform Study", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TASELISIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TELATINIB": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00952497", "title": "A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2012-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03175497", "title": "Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2019-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03817411", "title": "Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer", "status": "UNKNOWN", "last_update": "2019-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04798781", "title": "Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TELISOTUZUMAB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05005403", "title": "Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TEPOTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT05439993", "title": "Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TIVANTINIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01070290", "title": "A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen", "status": "WITHDRAWN", "last_update": "2014-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01152645", "title": "Study of ARQ 197 Monotherapy", "status": "COMPLETED", "last_update": "2017-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01611857", "title": "Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach", "status": "COMPLETED", "last_update": "2016-11-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB": { "n": 155, "n_observational": 16, "n_active": 59, "n_withdrawn": 5, "trials": [ { "nct": "NCT05150691", "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05274048", "title": "Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients", "status": "RECRUITING", "last_update": "2025-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05640830", "title": "Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy", "status": "RECRUITING", "last_update": "2024-11-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05965479", "title": "Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06085755", "title": "Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06121700", "title": "Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer", "status": "RECRUITING", "last_update": "2023-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253650", "title": "Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease", "status": "RECRUITING", "last_update": "2024-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364410", "title": "Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06468280", "title": "Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06504732", "title": "To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532006", "title": "A Phase \u2162 Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06572319", "title": "Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens", "status": "RECRUITING", "last_update": "2024-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06630130", "title": "Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06650332", "title": "Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients", "status": "RECRUITING", "last_update": "2024-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06730373", "title": "First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)", "status": "RECRUITING", "last_update": "2024-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06731478", "title": "Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764875", "title": "A Phase \u2162 Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07069712", "title": "A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07315750", "title": "A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07334431", "title": "Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07655024", "title": "TAIC FOLFOX for Locally Advanced G/GEJA", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07788196", "title": "A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00028535", "title": "Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00515411", "title": "Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2019-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01041404", "title": "ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2014-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130337", "title": "A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer", "status": "COMPLETED", "last_update": "2015-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01148849", "title": "Safety Study of MGAH22 in HER2-positive Carcinomas", "status": "COMPLETED", "last_update": "2025-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01191697", "title": "CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2025-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01228045", "title": "A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01260194", "title": "A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer", "status": "TERMINATED", "last_update": "2016-11-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01295086", "title": "Taxotere\u00ae, Eloxatin\u00ae and Xeloda\u00ae (TEX) in Combination With Herceptin\u00ae as Treatment for HER2 Positive Non-resectable Cancer", "status": "COMPLETED", "last_update": "2020-11-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01359397", "title": "Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01364493", "title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2017-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01384253", "title": "Safety Study of \u00b2\u00b9\u00b2Pb-TCMC-Trastuzumab Radio Immunotherapy", "status": "COMPLETED", "last_update": "2016-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01396707", "title": "Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX", "status": "COMPLETED", "last_update": "2020-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01402401", "title": "Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients", "status": "TERMINATED", "last_update": "2020-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01450696", "title": "A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer", "status": "TERMINATED", "last_update": "2016-11-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01461057", "title": "A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01472029", "title": "Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach", "status": "COMPLETED", "last_update": "2017-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01503983", "title": "Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive", "status": "COMPLETED", "last_update": "2015-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01579578", "title": "Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer", "status": "TERMINATED", "last_update": "2014-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602406", "title": "Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01641939", "title": "A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer", "status": "TERMINATED", "last_update": "2017-05-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01649271", "title": "Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.", "status": "COMPLETED", "last_update": "2025-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01702558", "title": "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)", "status": "TERMINATED", "last_update": "2021-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01736410", "title": "A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2013-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01746771", "title": "A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2016-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01748773", "title": "A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2019-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01774786", "title": "A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer", "status": "COMPLETED", "last_update": "2020-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01774851", "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach", "status": "TERMINATED", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928290", "title": "Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01939275", "title": "64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer", "status": "COMPLETED", "last_update": "2025-02-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02004769", "title": "Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2016-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02005484", "title": "A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression", "status": "TERMINATED", "last_update": "2014-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02030561", "title": "NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02158988", "title": "Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis", "status": "COMPLETED", "last_update": "2021-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205047", "title": "Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205463", "title": "KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer", "status": "WITHDRAWN", "last_update": "2014-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02250209", "title": "T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy", "status": "UNKNOWN", "last_update": "2014-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02380131", "title": "Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis", "status": "UNKNOWN", "last_update": "2015-03-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02393248", "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)", "status": "TERMINATED", "last_update": "2023-01-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02578368", "title": "Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction", "status": "COMPLETED", "last_update": "2024-11-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02581462", "title": "FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer", "status": "COMPLETED", "last_update": "2020-08-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02678182", "title": "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02725424", "title": "Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2022-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02726399", "title": "Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer", "status": "TERMINATED", "last_update": "2020-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02805829", "title": "Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02852096", "title": "Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks", "status": "UNKNOWN", "last_update": "2017-11-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02901301", "title": "Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954536", "title": "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer", "status": "COMPLETED", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319459", "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2021-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03329690", "title": "DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]", "status": "COMPLETED", "last_update": "2022-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03368196", "title": "DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein", "status": "COMPLETED", "last_update": "2022-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409848", "title": "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03556345", "title": "A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2", "status": "COMPLETED", "last_update": "2022-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03588533", "title": "Herzuma-capecitabine/Cisplatin for Gastric Cancer", "status": "UNKNOWN", "last_update": "2018-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03615326", "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)", "status": "COMPLETED", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03680560", "title": "Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers", "status": "TERMINATED", "last_update": "2020-03-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766607", "title": "Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer", "status": "WITHDRAWN", "last_update": "2019-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03783936", "title": "Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03950271", "title": "SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04014075", "title": "DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)", "status": "COMPLETED", "last_update": "2025-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04082364", "title": "Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04168931", "title": "Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC", "status": "TERMINATED", "last_update": "2023-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04249739", "title": "Pembrolizumab + Capecitabine\uff0fOxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive", "status": "UNKNOWN", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04281576", "title": "Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2024-11-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04309578", "title": "A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439110", "title": "Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2025-01-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "status": "TERMINATED", "last_update": "2023-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "status": "WITHDRAWN", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639219", "title": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04661150", "title": "A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction", "status": "COMPLETED", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704934", "title": "Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04714190", "title": "A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression", "status": "UNKNOWN", "last_update": "2023-12-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04819971", "title": "Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC", "status": "UNKNOWN", "last_update": "2023-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04888663", "title": "Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)", "status": "UNKNOWN", "last_update": "2021-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04908813", "title": "Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04989816", "title": "Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens", "status": "COMPLETED", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05002127", "title": "A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05034887", "title": "Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05143970", "title": "A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05190445", "title": "Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05207722", "title": "CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-12-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05218148", "title": "SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma", "status": "UNKNOWN", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311176", "title": "A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)", "status": "TERMINATED", "last_update": "2025-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311189", "title": "Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2022-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05515796", "title": "Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors", "status": "COMPLETED", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05555251", "title": "BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-12-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05678205", "title": "A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors", "status": "WITHDRAWN", "last_update": "2025-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05715931", "title": "Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05765357", "title": "Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin\u00ae in Healthy Male Volunteers", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05955833", "title": "89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study", "status": "COMPLETED", "last_update": "2026-05-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05980481", "title": "A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05997524", "title": "Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.", "status": "COMPLETED", "last_update": "2023-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06036745", "title": "Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06098898", "title": "Safety and Efficacy of NK510 to Treat Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-10-25", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06109467", "title": "Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06136897", "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06271837", "title": "A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06328738", "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06439550", "title": "Adjuvant Treatment With Serplulimab\uff0cTrastuzumab and SOX in the HER-2 Positive GC/GEJC", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06881017", "title": "Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998771", "title": "JSKN003 Combined Treatment of HER2-positive Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07040059", "title": "A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "TERMINATED", "last_update": "2026-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07126561", "title": "Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07257380", "title": "Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332533", "title": "A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07508956", "title": "Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07529613", "title": "Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2026-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07631884", "title": "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB DERUXTECAN": { "n": 27, "n_observational": 3, "n_active": 20, "n_withdrawn": 1, "trials": [ { "nct": "NCT05274048", "title": "Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients", "status": "RECRUITING", "last_update": "2025-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05965479", "title": "Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06085755", "title": "Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253650", "title": "Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease", "status": "RECRUITING", "last_update": "2024-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364410", "title": "Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06630130", "title": "Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06731478", "title": "Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764875", "title": "A Phase \u2162 Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07069712", "title": "A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03329690", "title": "DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]", "status": "COMPLETED", "last_update": "2022-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03368196", "title": "DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein", "status": "COMPLETED", "last_update": "2022-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04014075", "title": "DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)", "status": "COMPLETED", "last_update": "2025-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639219", "title": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704934", "title": "Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04989816", "title": "Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens", "status": "COMPLETED", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05034887", "title": "Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05678205", "title": "A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors", "status": "WITHDRAWN", "last_update": "2025-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06271837", "title": "A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07126561", "title": "Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07529613", "title": "Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2026-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB DUOCARMAZINE": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "status": "WITHDRAWN", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB EMTANSINE": { "n": 9, "n_observational": 1, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01641939", "title": "A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer", "status": "TERMINATED", "last_update": "2017-05-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01702558", "title": "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)", "status": "TERMINATED", "last_update": "2021-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439110", "title": "Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07126561", "title": "Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TUCATINIB": { "n": 9, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2025-01-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05190445", "title": "Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05382364", "title": "Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06157892", "title": "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07768358", "title": "Tucatinib Continuation Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" } ] }, "VANDETANIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00683787", "title": "Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer", "status": "TERMINATED", "last_update": "2015-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01183559", "title": "A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery", "status": "COMPLETED", "last_update": "2021-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "VARLITINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03130790", "title": "Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)", "status": "COMPLETED", "last_update": "2022-02-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05400915", "title": "Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients", "status": "COMPLETED", "last_update": "2023-11-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "X-82": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03511222", "title": "Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2020-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ZANIDATAMAB": { "n": 11, "n_observational": 1, "n_active": 7, "n_withdrawn": 0, "trials": [ { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07176312", "title": "Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04276493", "title": "Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05270889", "title": "Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial", "status": "UNKNOWN", "last_update": "2022-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07243938", "title": "Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07685704", "title": "Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ZOLBETUXIMAB": { "n": 15, "n_observational": 3, "n_active": 10, "n_withdrawn": 0, "trials": [ { "nct": "NCT06468280", "title": "Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06732856", "title": "A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer", "status": "RECRUITING", "last_update": "2025-07-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06901531", "title": "A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06962137", "title": "Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer", "status": "RECRUITING", "last_update": "2025-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01197885", "title": "Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01630083", "title": "Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer", "status": "COMPLETED", "last_update": "2025-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01671774", "title": "Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer", "status": "COMPLETED", "last_update": "2024-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03504397", "title": "A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03528629", "title": "A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "status": "COMPLETED", "last_update": "2024-12-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03653507", "title": "A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04086758", "title": "A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "status": "COMPLETED", "last_update": "2024-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06881017", "title": "Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] } } } }